Interneuron Pharmaceuticals Inc. (IPIC)
Patricia Lea of Vector Securities International initiated coverage with a "buy." She said the stock is likely to rise suddenly this year when the FDA announces that its Endocrine and Metabolic Drugs Advisory Committee will review IPIC's dexfenfluramine and Eli Lilly's Lovan (fluoxetine) to treat obesity. Her one year price target is $20.